Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on August 3, 2017 at 8:00 a.m. ET to discuss second quarter 2017 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 62118608. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres TherapeuticsSeres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

IR or PR Contact:Seres Therapeutics, Inc.Carlo Tanzi, Ph.D., 617-203-3467Head of Investor Relations and Corporate Communicationsctanzi@serestherapeutics.com

Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Seres Therapeutics Charts.
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Seres Therapeutics Charts.